Skip Navigation Links

European HIV Vaccine Alliance (EHVA)

European HIV Vaccine Alliance (EHVA): An EU Platform for the Discovery and Evaluation of Novel Prophylactic and Therapeutic Vaccine Candidates

ipal Investigator: Prof. Yves Levy

Baylor Principal Investigator: Gerard Zurawski, PhD

Funding Organization: European Commission

Project Start: 2015

Project End: 2020

 

Major Goal:

The European HIV Vaccine Alliance (EHVA) program has as major goal to develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials. This will be achieved by bringing together, within a highly-integrated and ambitious 5-year European program, internationally recognized experts from both public/academic and private sectors in the fields of immunology, virology, structural biology, viral vectors, statistics and computational science and clinical science. EHVA will also contribute to the field of HIV vaccines with a portfolio of highly-promising vaccine candidates that will be optimized and tested via the EHVA platform so as to be moved into larger clinical trials through EDCTP.



Copyright © 2019 Baylor Scott & White Health All Rights Reserved.   |   3500 Gaston Avenue, Dallas, TX 75246-2017   |   1.800.9BAYLOR
Site Map   |   Privacy Terms & Patient Rights   |   Terms of Use